Unlocking Orphan Pricing In France
Flawed System For Assessing Orphans Relies Too Heavily On Comparators
Heath technology assessments in the competitive orphan space, such as pulmonary arterial hypertension, could get tougher in France.
You may also be interested in...
The “chronic disease paradigm” presents a real challenge for companies marketing advanced therapies.
Value assessments of COVID-19 monoclonal antibodies should inform pricing decisions, says cross country coalition.
The company behind the CVnCOV COVID-19 vaccine candidate says the decision to withdraw from regulatory review is strategic. The EMA says outstanding issues affecting the benefit-risk balance remained to be answered at the time of withdrawal.